JOHN WHYTE: Welcome, everyone. I'm Dr. John Whyte. I'm the chief medical officer at WebMD. I'm here at the American Society of Clinical Oncology meeting, talking to my good friend, Elcin Barker Ergun, the president and CEO of Menarini Group. Elcin, it's great to see you again. JOHN WHYTE: I last saw you a year ago in Florence, where one of the best slides you've had that everyone has picked up is, you talked about there's a renaissance.
JOHN WHYTE: Now, something that's moving very fast is the topic of AI. And when you and I chatted a year ago, you were very measured about it. There are some folks who think it's going to change the whole drug development process and the way you treat patients. You were more like,"Hold on, John. It's a wait-and-see approach." How has your opinion changed, if at all?
ELCIN BARKER ERGUN: I'm really glad you brought that point again, because I feel we haven't made a leapfrog there. So it's still a very little, little improvement in the sense that some-- ELCIN BARKER ERGUN: You're right. I think the issue is fit. Correctly, in the beginning, it was more about how do we make sure there's a pipeline coming.
JOHN WHYTE: One area where there is a lot of drug development is the area of cardiovascular. And you and I have talked about it as well last year. What's your current assessment of where we are in the cardiovascular space? ELCIN BARKER ERGUN: Correct. I think in areas like metabolic-related obesity, we've seen really, really breakthroughs. But when you come to cardiovascular, you have anti-thrombosis--